Steris (STE) reported $1.42 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 2.5%. EPS of $2.41 for the same period compares to $2.30 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.46 billion, representing a surprise of -3.07%. The company has not delivered EPS surprise, with the consensus EPS estimate being $2.41.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

Steris (STE) came out with quarterly earnings of $2.41 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $2.30 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical products maker would post earnings of $2.17 per share when it actually produced earnings of $2.22, delivering a surprise of 2.30%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Steris, which belongs to th ...

Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year • Total fiscal 2024 revenue increase 12% to $5.5 billion • Total fiscal 2024 U.S. GAAP earnings per diluted share of $3.81; adjusted earnings per diluted share increase to $8.83 • Targeted restructuring plan announced DUBLIN, IRELAND - (May 8, 2024) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 fourth quarter ended March 31, 2024. Total revenue for the fou ...

文章核心观点 - 公司2024财年总收入增长12%至55亿美元 [1][2] - 公司2024财年调整后每股收益增长至8.83美元 [4][5] - 公司宣布实施目标性重组计划 [13][14] 财务业绩总结 - 2024财年第四季度总收入同比增长10%至15亿美元 [1] - 2024财年第四季度持续经营业务的常汇率有机收入同比增长7%至14亿美元 [1] - 2024财年总收入同比增长12%至55亿美元,持续经营业务的常汇率有机收入同比增长10%至50亿美元 [2] - 2024财年第四季度GAAP净亏损为140万美元,调整后净收益为2.58亿美元 [4] - 2024财年GAAP净收益为3.78亿美元,调整后净收益为8.78亿美元 [5] 业务板块表现 - 医疗保健板块第四季度收入同比增长14%至10.08亿美元,经营利润增长 [7] - 应用消毒技术板块第四季度收入同比增长5%至2.51亿美元,经营利润增长 [8] - 生命科学板块第四季度收入同比增长2%至1.61亿美元,经营利润增长 [9][10] - 牙科板块第四季度收入持平至1.04亿美元,经营利润增长 [11] 现金流和重组计划 - 2024财年经营活动产生的现金流为9.73亿美元,自由现金流为6.20亿美元 [12] - 公司宣布实施目标性重组计划,预计将产生约1亿美元的税前重组费用 [13][14] 2025财年展望 - 2025财年持续经营业务收入预计增长6.5%-7.5%,常汇率有机收入预计增长6%-7% [15][16] - 2025财年调整后每股收益预计在9.05-9.25美元之间 [16] - 2025财年资本支出预计约3.60亿美元,自由现金流预计约7亿美元 [16]

STERIS plc (STE) is likely to grow in the coming quarters, backed by the promising recovery potential in the AST (Applied Sterilization Technologies) segment. The company also benefits from the growing healthcare and pharmaceutical sectors, fueled by an aging population and strategic acquisitions like the BD assets purchase. Strong solvency buoys optimism.Meanwhile, headwinds such as foreign currency risks and macroeconomic challenges raise worry for the stock.In the past year, shares of this Zacks Rank #3 ...

公司业绩 - STERIS plc (STE) 预计将发布2024财年第四季度业绩[1] - STE在过去四个季度中，三次超过盈利预期，一次未达预期，平均超出预期为3.96%[1] - 上一季度，公司每股调整后盈利为2.22美元，超出Zacks Consensus Estimate 2.30%[2] - Zacks Consensus Estimate显示，STERIS第四季度2024财年的收入预计为14.7亿美元，同比增长5.8%[13] - Zacks Consensus Estimate显示，STERIS第四季度2024财年的每股盈利预计为2.43美元，同比增长5.7%[14] Healthcare部门 - Healthcare部门预计在第四季度保持强劲势头[3] - 预计资本设备、消耗品和服务的增长将强劲，主要受美国手术量的反弹、价格和市场份额增长的推动[4] - 我们的模型预计，Healthcare部门第四季度的收入将比去年同期报告的数字提高6.6%[6] - 在Healthcare部门内，先前的表现受到MedTech库存去库存和生物加工客户需求减少的影响[7] - STE在过去几个季度中看到MedTech需求的复苏迹象[8] - 我们假设这一趋势在即将报告的季度中也将持续，有利于STERIS的收入[9] AST部门和Life Sciences部门 - 我们预计AST部门第四季度的收入将同比增长3.6%[9] - 我们预计Life Sciences部门将受益于资本发货时间的安排，有利于其收入[10] - 我们的模型预计，Life Sciences部门第四季度的收入将比去年同期增加2%[11] Dental部门 - Dental部门在第三季度面临来自一家大客户减少订单的挑战，可能会影响第四季度的EBIT利润率[12] 股票评级 - 根据我们的模型，具有Zacks Rank 1（强烈买入）、2（买入）或3（持有）的股票，以及正面的盈利ESP，有更高的击败预期的机会，但这里并非如此[15] - STERIS的盈利ESP为0.00%，公司目前持有Zacks Rank 2[16]

HuFriedyGroup - Peak Rock Capital的附属公司签署了收购STERIS plc的牙科部门的最终协议[1] - HuFriedyGroup是一家成立于1908年的领先全球制造商，拥有行业领先品牌[2] - HuFriedyGroup总部位于芝加哥，服务于约100个国家，拥有1500多名员工和20多个全球制造设施[3]

股票走势分析 - Steris (STE) 最近出现了明显的下降趋势，股票在过去四周下跌了9.1%[1] - RSI指标显示STE股票的卖空压力正在逐渐消耗，股票的趋势可能很快会逆转，达到供需的平衡[4] 预期收益分析 - 分析师普遍认为STE公司有望报告比之前预测更好的收益，这也是股票可能逆转的一个因素[8]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style S ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?T ...